Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03404661 · ClinicalTrials.gov registry record
Optical and Biochemical Biomarkers in Early Pancreatic Cancer
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 346
- Enrollment target
NCT03404661: Completed study, sponsored by Mayo Clinic.
NCT03404661 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 346 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03404661 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 346 participants
- Enrollment target
Study Summary
The purpose of this study is to develop a test for detection of pancreatic cancer by looking at the subject's DNA.
Primary Outcome
After pancreatic juice is collected, top 10 markers for pancreas cancer detection will be done from discovery and validation on tissue (AUC\>.95) and from pilot pancreatic-juice testing (AUCs \>0.9).
Interventions
- DRUG Synthetic Human Secretin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2018-01-11 |
| Est. Completion | 2022-03-10 |
What the finished NCT03404661 record still lists
NCT03404661 is an observational study that tracks outcomes without assigning an intervention. The registered 346 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Synthetic Human Secretin is the first listed.
NCT03404661 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03404661 about?
NCT03404661 is a clinical study titled "Optical and Biochemical Biomarkers in Early Pancreatic Cancer". The purpose of this study is to develop a test for detection of pancreatic cancer by looking at the subject's DNA.
What is the current status of trial NCT03404661?
This trial is currently completed. The enrollment target is 346 participants. The study started on 2018-01-11. Estimated completion is 2022-03-10.
What interventions are being tested in trial NCT03404661?
The interventions under investigation include: Synthetic Human Secretin (DRUG).
Who is sponsoring clinical trial NCT03404661?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267886 · 346 participants · Phase 4
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
- NCT06705842 · 346 participants · Phase 4
APPI-Cost Trial for Perforated Appendicitis
- NCT06932887 · 346 participants · Phase 3
The Beat Pain Better Trial
- NCT01742143 · 347 participants
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI